Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32 (discussion 32–3).

Article  PubMed  Google Scholar 

Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881–8.

Article  CAS  PubMed  Google Scholar 

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27(12):4795–801.

Article  PubMed  Google Scholar 

Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793–8.

Article  PubMed  Google Scholar 

Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549–55.

Article  PubMed Central  PubMed  Google Scholar 

National Comprehensive Cancer Network: National Comprehensive Cancer Network, Inc. 2024; 2024. Available at: http://www.nccn.org.

Caudle AS, Kuerer HM. Targeting and limiting surgery for patients with node-positive breast cancer. BMC Med. 2015;13(1):149.

Article  PubMed Central  PubMed  Google Scholar 

Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159–65.

Article  CAS  PubMed  Google Scholar 

Mallin K, Browner A, Palis B, Gay G, McCabe R, Nogueira L, et al. Incident cases captured in the national cancer database compared with those in U.S. population based central cancer registries in 2012–2014. Ann Surg Oncol. 2019;26(6):1604–12.

Article  PubMed  Google Scholar 

Barrio AV, Montagna G, Mamtani A, Sevilimedu V, Edelweiss M, Capko D, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event. JAMA Oncol. 2021;7(12):1851–5.

Article  PubMed  Google Scholar 

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305.

Article  PubMed Central  PubMed  Google Scholar 

Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, et al. Changes in surgical management of the axilla over 11 years—report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30(11):6401–10.

Article  PubMed  Google Scholar 

Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A. Patterns in the use of axillary operations for patients with node-positive breast cancer after neoadjuvant chemotherapy: a national cancer database (NCDB) analysis. Ann Surg Oncol. 2019;26(10):3305–11.

Article  PubMed  Google Scholar 

Peery GB, Pak J, Burkbauer L, Agala CB, Selfridge JM, Gallagher KK, Spanheimer PM. Omission of axillary dissection in node positive breast cancer after neoadjuvant systemic therapy. J Surg Res. 2023;292:247–57.

Article  PubMed  Google Scholar 

Park Y, Shin YS, Kim K, Shin KH, Chang JH, Kim SS, et al. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: a retrospective multicenter study (KROG 21-06). Eur J Surg Oncol. 2023;49(3):589–96.

Article  PubMed  Google Scholar 

Montagna G, Laws A, Ferrucci M, Mrdutt M, Polidorio N, Sevilimedu V, et al. Abstract GS02-02: Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study. Cancer Res. 2024;84(9 Suppl):GS02.

Google Scholar 

Weiss A, Colugnati F, Mitchell M, Li Y, Marin C, Gergelis KR, et al. Contemporary axillary surgical management in patients with pathologically node positive disease after neoadjuvant chemotherapy: a survey of members of the American Society of Breast Surgeons. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15705-y.

Article  PubMed Central  PubMed  Google Scholar 

Rosenberger LH, Ren Y, Thomas SM, Greenup RA, Fayanju OM, Hwang ES, Plichta JK. Axillary lymph node dissection in node-positive breast cancer: Are ten nodes adequate and when is enough, enough? Breast Cancer Res Treat. 2020;179(3):661–70.

Article  CAS  PubMed  Google Scholar 

Chun JW, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, et al. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy. Sci Rep. 2021;11(1):9056.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Cabıoğlu N, Karanlık H, Yıldırım N, Müslümanoğlu M, Çakmak Karadeniz G, Trabulus Can D, et al. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021;47(10):2506–14.

Article  PubMed  Google Scholar 

Plichta JK, Rushing CN, Lewis HC, Rooney MM, Blazer DG, Thomas SM, et al. Implications of missing data on reported breast cancer mortality. Breast Cancer Res Treat. 2023;197(1):177–87.

Article  PubMed  Google Scholar